An observational study in Hepatitis D, sponsored by HepNet Study House, German Liverfoundation. Completed at 18 sites in 12 countries. Per ClinicalTrials.gov, last updated 2022-06-02.
Sponsored by HepNet Study House, German Liverfoundation · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Hepatitis D with a site in Germany — 3 open to participants now, 9 under way, 4 of them phase 3. Hepatitis D · Germany.
Among the 13 studies in Hepatitis D with a site in Germany, this one is the only one that started in 2013, is one of 4 observational ones, and was the 2nd registered.
63 studies on the registry are indexed under Hepatitis D; 21 are open to participants now.
Browse Hepatitis D studies →3 of the 13 studies in Hepatitis D with a site in Germany are open now. Recruiting first, the newest first:
Mirum Pharmaceuticals, Inc. · Sites in Germany, Austria, Czechia and 9 more countries
Ages 18–99
University Hospital, Bonn · Sites in Germany
Ages 18+
Hannover Medical School · Sites in Germany, Italy, Romania and 1 more country
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 14 Hepatitis D studies recruiting now, 9 (64%) set no upper age limit and 1 (7%) stops at 75 or younger; 3 take children under 18; 2 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 1 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 2,000 is above the median of 326 across 29 observational studies indexed under Hepatitis D.
Median enrollment 124 across the 9 interventional studies, 1,375 across the 4 observational. Of the 4 that completed or were terminated, 1 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 13 have an industry lead sponsor. The 7 most frequent:
HepNet Study House, German Liverfoundation is the lead sponsor of 7 studies on the registry; none are open to participants now.
HepNet Study House, German Liverfoundation has 2 studies filed under Hepatitis D — fewer than ten, so there is no comparison to draw.
3 of the studies in Hepatitis D with a site in Germany that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07128550Phase 3Vir Biotechnology, Inc.A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide | 2026-12 |
| NCT07200908Phase 3Mirum Pharmaceuticals, Inc.A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2) | 2027-06-30 |
| NCT06160635Hannover Medical SchoolD-SOLVE Cohorts (Cohort A and B) | 2027-09-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 13 studies in Hepatitis D with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Hepatitis delta is a major health problem, not only because of the severity of the disease, but also due to the lack of effective antiviral treatment. To improve the current therapeutic options, a better understanding of the pathophysiology is essential. Reliable research in this direction is only possible with large patient study groups. However, given the geographic distribution of hepatitis delta, larger patient cohorts would only be possible through multicenter collaboration.
The hepatitis international network cohort is a multicenter, observational study that will build up a research registry of HDV patients all over the world.
The aims of this project are:
i. Collect clinical information from hepatitis delta patients from multiple centers distributed worldwide in order to build up a large database that will enable and facilitate further research on chronic hepatitis delta.
ii. To better inform patients about their viral infection, present status and evolution of liver disease throughout time. To give them the tools needed to inform other peers and medical professionals about the significance and consequences of a chronic hepatitis delta infection.
iii. To allow the participating physicians to track course of the disease, therapies, signs and symptoms of the hepatitis delta patients included by their center.
Patients with chronic hepatitis delta will be screened regardless of HDV or HBV genotype
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Absence of any cause of relevant liver disease other than HDV (i.e. hemochromatosis, hepatitis, alcoholic or toxic liver disease, etc.)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Proportion of chronic hepatitis B patients with chronic hepatitis D infection worldwide
Time frame: 10 years
HDV-RNA HBsAg
Time frame: 10 years
HBV-DNA
Time frame: 10 years
Proportion of treated chronic hepatitis B patients with chronic hepatitis D infection worldwide
Time frame: 10 years
Ran from Nov 2013 to primary completion in May 2022, 102 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
HepNet Study House, German Liverfoundation